Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

Sarah Faiz 1 Jonathan Giovannelli 2, 1 Céline Podevin 2 Marie Jachiet 3 Jean-David Bouaziz 3 Ziad Reguiai 4 Audrey Nosbaum 5 Audrey Lasek 6 Marie-Christine Ferrier Le Bouedec 7 Aurélie Du Thanh 8 Nadia Raison-Peyron 8 Florence Tetart 9 Anne-Benedicte Duval-Modeste 10 Laurent Misery 11 François Aubin 12 Anne Dompmartin 13 Cécile Morice 14 Catherine Droitcourt 15 Angele Soria 16, 17 Jean-Philippe Arnault 18 Juliette Delaunay 19 Emmanuel Mahé 20 Marie-Aleth Richard 21 Amélie Schoeffler 22 Jean-Philippe Lacour 23 Edouard Begon 24 Amélie Walter-Lepage 25 Anne-Sophie Dillies 26 Sandrine Rappelle-Duruy 27 Stéphane Barete 28 Nathalia Bellon 29 Nathalie Beneton 30 Aude Valois 31 Sébastien Barbarot 32 Julien Sénéchal 33 Delphine Staumont-Sallé 2, 1
5 Immunologie de l'allergie cutanée et vaccination – Immunology of skin allergy and vaccination
CIRI - Centre International de Recherche en Infectiologie - UMR
Abstract : Background Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials. Objective We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort. Methods We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up. Results We included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10−9 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10−9, respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm3) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10−6). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs. Limitations No control group, missing data. Conclusion This real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-02321685
Contributeur : Marion Boutin <>
Soumis le : lundi 21 octobre 2019 - 14:11:52
Dernière modification le : jeudi 12 décembre 2019 - 11:09:43

Identifiants

Citation

Sarah Faiz, Jonathan Giovannelli, Céline Podevin, Marie Jachiet, Jean-David Bouaziz, et al.. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. Journal of The American Academy of Dermatology, Elsevier, 2019, 81 (1), pp.143-151. ⟨10.1016/j.jaad.2019.02.053⟩. ⟨hal-02321685⟩

Partager

Métriques

Consultations de la notice

28